Summan-We studied the effect of early postoperative chemotherapy. including 5-fluorouracil (5-FU) for 5 davs for patients With gastric cancer following noncurative resection. The study was (Schabel. 1975 : Gunduz et al.. 1979 . hence. tumour foci remaining after a noncurative resection are expected to be more sensitive to cell-cycle specific drugs. For these reasons. intensive remission-induction followed bv maintenance therapy should be given due consideration. 5-Fluorouracil (5-FU) administration has been prescribed for 5 days for the patients with advanced gastric cancer. in combination with MMC and other drugs (Haller. 1988) . In 162 patients. we examined the effect of adding 5-FU bolus injections for 5 days during induction therapy With MMC and OK432 (Maehara et al.. 1990a).
endoscopy. extensive lymph node dissection : Boku et al.. 1989 ) and postoperative adjuvant chemotherapy (Kano et al.. 1981: Gastrointestinal Tumor Study Group. 1982; Inokuchi et al.. 1984 ) have led to a longer survival time for approximately 60% of curatively resected patients. Patients With a far advanced cancer are usually treated by palliative resection. As tumour foci remain in these patients. antitumour drugs are required to suppress tumour growth. Kano et al. (1982) reported that postoperative long-term cancer chemotherapy (PLCC) with a combination of mitomycin C (MMC). 1-(2-tetrahydrofurvl)-5-fluorouracil (tegafur) and PSK led to a life-prolongation for patients With noncuratively resected stage IV gastric cancer. however. the clinical effects are not satisfactory. The doubling time of tumour cells in a small population focus is often shorter than in a larger population focus (Schabel. 1975 : Gunduz et al.. 1979 . hence. tumour foci remaining after a noncurative resection are expected to be more sensitive to cell-cycle specific drugs. For these reasons. intensive remission-induction followed bv maintenance therapy should be given due consideration. 5-Fluorouracil (5-FU) administration has been prescribed for 5 days for the patients with advanced gastric cancer. in combination with MMC and other drugs (Haller. 1988) . In 162 patients. we examined the effect of adding 5-FU bolus injections for 5 days during induction therapy With MMC and OK432 (Maehara et al.. 1990a ).
Materials and methods

Patients
All patients included in the prospectively randomised and controlled trial underwent a macroscopic noncurative gastric resection. The 186 patients were entered into this studv between July 1986 and June 1988. The patients were assigned. at random. to either group A or B on the day of operation. The protocol (Figure 1 ) was as follows. The inductive regimen for group A included mitomycin C (MMC) (Inokuchi et al.. 1984) 
Results
In the 186 patients. entered into this study. 19 (10.2%) had to be excluded: four had double cancers. eight no surgical resection. two over 76 years of age at operation and five macroscopic curative resections. and five (2.7%) dropped out in the course of treatment; two no ingestion of any drug and three in group A who were inadequately given 5-FU injections. The patients were followed in the outpatient department at 2 week intervals. Attention was directed to their general condition. bone marrow function, liver function and serum carcinoembryonic antigen levels (Maehara et al.. 1990a ). and at 6 month intervals imagings were taken.
Clinicopathological features
Clinicopathological details on the 162 eligible cases (87.10): 82 in group A; 80 in group B. are shown in Table I . There were no significant differences between the groups with regard to the distnrbution of prognostic factors. With respect to surgical procedures: gastric resection and lymph node dissection. there were no differences between the groups. The clinicopathological factors related to palliative resection are shown in Table II . There was no difference between them. Doses of drugs There was no difference in the dose of each drug between groups A and B. as shown in Table III .
Survival rates for patients in groups A and B Figure 2 shows the survival curves of 82 patients in group A and 80 in group B. Generalised Wilcoxon test of the two survival patterns revealed a P value of 0.169. The 50% survival was 8.9 months for those in Group A and 12.9 months for those in group B. The 1-year survival rate was 35.5% for group A and 49.0% for group B and the 2-year survival rate was 19.9% for group A and 28.10% for group B. (Kano et al.. 1981; Inokuchi et al., 1984) . A delay in postoperative treatment can lead to negative results (Higgins et al.. 1983; Engstrom et al., 1985) . Fielding et al. (1983) found no positive effects of adjuvant chemotherapy with MMC plus 5-FU. but survival time was lengthened when treatment was begun within 1 month. Douglass (1985) reported that postoperative chemotherapy should be initiated at the time of surgical resection. As tumour cells remaining after noncurative resection may grow rapidly in the postoperative period (Schabel. 1975; Gunduz et al.. 1979) . the potential to control the remaining tumour foci is reduced significantly by delaying chemotherapy further in the postoperative period. The PLCC regimen. which consists of intermittent administration of MMC and long-term continuous administration of tegafur and PSK. has lengthened the survival time of patients with gastric cancer following noncurative resection (Kano et al.. 1982) . We found that the combination chemotherapy of MMC, tegafur plus PSK improves the 15-year survival of patients with advanced gastnrc cancer (Maehara et al., 1990c) . In an attempt to improve survival by initiating aggressive chemotherapy early, 5-FU bolus injections were added to the chemotherapy regimen. As UFT is more effective than tegafur for patients with stage IV gastric cancer (Maehara et al.. 1990b), we prescribed UFT and PSK for 1 year, for both groups. 5-FU has been prescribed for 5 days, in combination with other drugs to treat patients with advanced gastric cancer (Gastrointestinal Tumor Study Group, 1988) . The rate of myelotoxicity of 5-FU is lower in those treated with continuous infusion, than in those given a bolus injection, in cases of high dose administration (Seifet et al., 1975; Fraile et al., 1980 ). An adequate anastomotic healing has been ensured. We prescribed a bolus injection of 250 mg of 5-FU for 5 days. The incidence of side effects did not increase in the group B, by adding 5-FU infusion to the same regimen given to group A. This induction chemotherapy with MMC and 5-FU (MF) was safe for the patients. The 1 year survival rate was 35.5°in group A, for whom the drug protocol was similar to that of PLCC (Kano et al., 1982) , and the rate was 49.0% in group B on the aggressive chemotherapy.
Although there was no definite statistical difference, the 50% survival rate improved 1.4-fold in cases of aggressive chemotherapy, that is when 5-FU injection was added in the very early postoperative period. Retrospective analysis showed that this protocol is effective for patients with gastric cancer of the differentiated, but not for the undifferentiated type. A prospective study based on the histopathology is in progress.
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